ICIs, anti-PD-1/anti-PD-L1 and anti-CTLA4, were the first immunotherapy agents to be approved for the treatment of NSCLC, although many other alternatives to these inhibitors are being evaluated in numerous clinical trials. This evidence concerns the gene RPL17 and non-small cell lung carcinoma.